Business Segments · Total Assets
Life Sciences and Diagnostics Markets — Total Assets
Agilent Technologies Life Sciences and Diagnostics Markets — Total Assets increased by 0.9% to $6.00B in Q2 2025 compared to the prior quarter.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ4 2024
Last reportedQ1 2026
Rolls up toTotal Assets
How to read this metric
Growth in assets relative to revenue may indicate capital investment for future capacity, while declining assets might suggest divestiture or improved asset efficiency.
Detailed definition
This metric represents the total economic resources controlled by the life sciences and diagnostics segment, including p...
Peer comparison
Standard segment asset reporting required under segment disclosure accounting standards for public companies.
Metric ID:
a_segment_life_sciences_and_diagnostics_markets_assetsHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | |
|---|---|---|---|---|
| Value | $5.87B | $5.79B | $5.95B | $6.00B |
| QoQ Change | — | -1.3% | +2.7% | +0.9% |
Range$5.79B – $6.00B
Current Streak2 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Agilent Technologies's life sciences and diagnostics markets — total assets?
- Agilent Technologies (A) reported life sciences and diagnostics markets — total assets of $6.00B in Q2 2025.
- What does life sciences and diagnostics markets — total assets mean?
- The total value of all resources and assets dedicated to the life sciences and diagnostics business segment.